According to filings with the U.S. Securities and Exchange Commission, Serotiny is raising $4,500,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Colin Farlow played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Serotiny
Serotiny is a therapeutic discovery company that designs new genes for next generation cell & gene therapies. We invent therapeutic multi-domain proteins in high-throughput by orchestrating software, mammalian synthetic biology, and therapeutic expertise. At the heart of Serotinys technology is a discovery platform involving the close interworking of computationally aided protein design, high-throughput cellular assays, and sophisticated data-driven analytics, which together enable Serotiny to engineer multi-domain proteins for cell therapies, like Chimeric Antigen Receptors used in CAR-T immunotherapies and second-generation Cas9-based gene editing tools, like Base and Prime Editors. Rationally designing proteins for cell & gene therapies requires a different set of constraints and design tools than enzyme or antibody engineering. These therapeutic multi-domain proteins will not be purified, they will be expressed in a human cell, and they will affect the therapeutic phenotype of that cell. Serotiny encodes these constraints into its platform to create a scaled design-build-test-learn process to quickly and efficiently generate therapeutic candidates for next-generation therapies. Serotiny is a multidisciplinary team with expertise including molecular biology, immunology, machine learning, software engineering, data science, and bioinformatics. Were looking for passionate and creative people to join our team!

To learn more about Serotiny, visit http://serotiny.com/

Contact:
Colin Farlow, Chief Executive Officer
415-742-1139

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.